Artículo
Therapeutic potential of LINS01 histamine H3 receptor antagonists as antineoplastic agents for triple negative breast cancer
Ospital, Ignacio Agustin
; Táquez Delgado, Mónica Alejandra
; Nicoud, Melisa Beatriz
; Corrêa, Michelle F.; Borges Fernandes, Gustavo A.; Andrade, Isabela W.; Lauretta, Paolo; Martínez Vivot, Rocío
; Comba, María Betina
; Zanardi, Maria Marta
; Speisky, Daniela Lorena; Uriburu, Juan L.; Fernandes, João P. S; Medina, Vanina Araceli
Fecha de publicación:
04/2024
Editorial:
Elsevier France-Editions Scientifiques Medicales Elsevier
Revista:
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
ISSN:
0753-3322
e-ISSN:
1950-6007
Idioma:
Inglés
Tipo de recurso:
Artículo publicado
Clasificación temática:
Resumen
he aims of this work were to evaluate the expression of histamine H3 receptor (H3R) in triple negative breast cancer (TNBC) samples and to investigate the antitumoral efficacy and safety of the LINS01 series of H3R antagonists, through in silico, in vitro, and in vivo approaches. Antitumor activity of LINS01009, LINS01010, LINS01022, LINS01023 was assayed in vitro in 4T1 and MDA-MB-231 TNBC cells (0.01–100 μM), and in vivo in 4T1 tumors orthotopically established in BALB/c mice (1 or 20 mg/kg). Additionally, H3R expression was assessed in 50 human TNBC samples. We have described a higher H3R mRNA expression in basal-like/TNBC tumors vs. matched normal tissue using TCGA Pan-Cancer Atlas data, and a higher H3R expression in human tumor samples vs. peritumoral tissue evidenced by immunohistochemistry associated with poorer survival. Furthermore, while all the essayed compounds showed antitumoral properties, LINS01022 and LINS01023 exhibited the most potent antiproliferative effects by: i) inducing cell apoptosis and suppressing cell migration in 4T1 and MDA-MB-231 TNBC cells, and ii) inhibiting cell growth in paclitaxel-resistant 4T1 cells (potentiating the paclitaxel antiproliferative effect). Moreover, 20 mg/kg LINS01022 reduced tumor size in 4T1 tumor-bearing mice, exhibiting a safe toxicological profile and potential for druggability estimated by ADME calculations. We conclude that the H3R is involved in the regulation of TNBC progression, offering promising therapeutic potential for the novel LINS01 series of H3R antagonists.
Palabras clave:
HISTAMINE
,
BREAST CANCER
,
RH3
Archivos asociados
Licencia
Identificadores
Colecciones
Articulos(BIOMED)
Articulos de INSTITUTO DE INVESTIGACIONES BIOMEDICAS
Articulos de INSTITUTO DE INVESTIGACIONES BIOMEDICAS
Articulos(CCT - ROSARIO)
Articulos de CTRO.CIENTIFICO TECNOL.CONICET - ROSARIO
Articulos de CTRO.CIENTIFICO TECNOL.CONICET - ROSARIO
Citación
Ospital, Ignacio Agustin; Táquez Delgado, Mónica Alejandra; Nicoud, Melisa Beatriz; Corrêa, Michelle F.; Borges Fernandes, Gustavo A.; et al.; Therapeutic potential of LINS01 histamine H3 receptor antagonists as antineoplastic agents for triple negative breast cancer; Elsevier France-Editions Scientifiques Medicales Elsevier; Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie; 174; 4-2024; 1-15
Compartir
Altmétricas